China discovers new bat coronavirus HKU5-CoV-2: How serious is the threat?

Pallavi Madhiraju- February 22, 2025 0

A newly identified bat coronavirus, HKU5-CoV-2, has been discovered by Chinese scientists, raising concerns about animal-to-human transmission and its potential public health implications. The virus ... Read More

Pfizer’s ADCETRIS combination regimen secures FDA approval for relapsed large B-cell lymphoma

Pallavi Madhiraju- February 12, 2025 0

The U.S. Food and Drug Administration (FDA) has approved Pfizer Inc.’s supplemental Biologics License Application (sBLA) for ADCETRIS (brentuximab vedotin) in combination with lenalidomide and ... Read More

FDA approves EMBLAVEO to combat complicated intra-abdominal infections with limited treatment options

Pallavi Madhiraju- February 9, 2025 0

The U.S. Food and Drug Administration (FDA) has granted approval for EMBLAVEO (aztreonam and avibactam), marking a significant milestone in the fight against complicated intra-abdominal ... Read More

Pfizer reports strong Q4 2024 earnings, reaffirms 2025 guidance amid cost-cutting strategy

Pallavi Madhiraju- February 4, 2025 0

Pfizer Inc. delivered strong fourth-quarter 2024 earnings, exceeding analyst expectations and demonstrating resilience in a challenging pharmaceutical market. The company reaffirmed its 2025 financial guidance, ... Read More

Pfizer resolves $59.7m kickback allegations linked to Biohaven’s marketing practices

Pallavi Madhiraju- January 27, 2025 0

Pharmaceutical giant Pfizer Inc., acting on behalf of its subsidiary Biohaven Pharmaceutical Holding Company Ltd., has agreed to a $59.7 million settlement to resolve allegations ... Read More

Pfizer’s BRAFTOVI regimen doubles response rates for metastatic colorectal cancer

Pallavi Madhiraju- January 26, 2025 0

Pfizer Inc. has unveiled compelling findings from the Phase 3 BREAKWATER trial, highlighting the efficacy of its BRAFTOVI (encorafenib) combination regimen in treating metastatic colorectal ... Read More

Zai Lab and Pfizer collaborate to address drug-resistant infections in China

Pallavi Madhiraju- November 23, 2024 0

Zai Lab and Pfizer have entered a partnership to commercialize XACDURO (sulbactam-durlobactam) in mainland China, addressing the rising threat of drug-resistant infections caused by carbapenem-resistant ... Read More

Pfizer stuns Wall Street with booming Q3 earnings and new guidance boost

Pallavi Madhiraju- October 29, 2024 0

Pfizer Inc. delivered a financial jolt in its third quarter of 2024, surpassing Wall Street’s expectations and raising its annual revenue and earnings guidance for ... Read More

FDA approves Pfizer’s HYMPAVZI for breakthrough hemophilia treatment

Pallavi Madhiraju- October 13, 2024 0

In a major leap for hemophilia patients, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has granted approval for HYMPAVZI ... Read More

Pfizer to offload 540 million shares in shocking Haleon sale—What does this mean for the healthcare giant?

Pallavi Madhiraju- September 30, 2024 0

In a blockbuster move set to shake up the market, Pfizer has announced its plan to sell approximately 540 million ordinary shares in Haleon, one ... Read More